secwatch / observer
8-K filed May 1, 2026, 7:59 PM ET ticker TNXP CIK 0001430306
earnings confidence medium sentiment negative materiality 0.65

Tonix reports preliminary Q1 net loss $40.8M, cash $185.5M, revenue $6.9M

Tonix Pharmaceuticals Holding Corp.

2026-Q1 EPS reported -$2.93 vs consensus -$2.48 ▼ miss (-18.0%)

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. reported quarter ended March 31, 2026 results: revenue approximately $6.9 million, net income approximately $40.8 million.

Period
quarter ended March 31, 2026
Revenue
approximately $6.9 million
Net income
approximately $40.8 million
Result
preliminary results
Exact text from the filing
to $16.8 million for the quarter ended March 31, 2025. · The Company’s net revenue from sales of its marketed products for the quarter ended March 31, 2026, was approximately $6.9 million compared to $2.4 million for the quarter ended March 31, 2025. o Net revenue from sales of Zembrace® SymTouch ® and Tosymra ® for the quarter ended March 31, 2026, was
View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR
accession 0001999371-26-009744
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.